RZLT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 geg. 2024 @ 23:00):

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States...

Stats
Šios dienos apimtis	162 061
Vidutinė apimtis	346 269
Rinkos kapitalizacija	114.36M
EPS	$0 ( 2024-05-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.59
ATR14	$0.0220 (0.78%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Roberts Brian Kenneth	Buy	500	Common Shares
2022-07-22	Handok, Inc.	Buy	3 157 895	Common Shares
2021-10-15	Handok, Inc.	Buy	769 231	Common Shares
2024-03-15	Evans Daron	Buy	20 000	Common Shares
2024-03-14	Roberts Brian Kenneth	Buy	10 000	Common Shares

INSIDER POWER
100.00
Last 96 transactions
Buy: 107 305 216 \| Sell: 58 571 575

Tūris Koreliacija

Ilgas: -0.11 (neutral)

Trumpas: 0.90 (strong)

Signal:(54.094) Same movement expected

Rezolute, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
XBIT	0.97
MTEK	0.968
VNOM	0.967
FANG	0.963
ENTX	0.961
PRIM	0.958
APP	0.954
SVFAU	0.954
IXAQ	0.951
AEAC	0.951

10 Labiausiai neigiamai susiję koreliacijos
HCDIP	-0.96
AKTX	-0.959
HAIN	-0.95
EMBC	-0.947
SPTN	-0.94
SHEN	-0.939
XPON	-0.936
UONEK	-0.934
PEAR	-0.934
BPTH	-0.933

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Rezolute, Inc. Koreliacija - Valiuta/Žaliavos

0.55
( weak )

0.29
( neutral )

0.00
( neutral )

0.82
( strong )

0.80
( moderate )

-0.60
( weak negative )

Rezolute, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-382 000 (0.00 %)
EPS:	$-1.010

FY	2023
Pajamos:	$0
Bruto pelnas:	$-382 000 (0.00 %)
EPS:	$-1.010

FY	2022
Pajamos:	$0
Bruto pelnas:	$-256 000 (0.00 %)
EPS:	$-2.13

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.72

Financial Reports:

No articles found.

Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.